CLN-049

CLN-049 · Cullinan Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CLN-049, covering 2026-01-16 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]

See pricing